Inhibition of SIRPα in dendritic cells potentiates potent antitumor immunity. (1st September 2016)

• Record Type: Journal Article
• Authors: Liu, Qiong; Wen, Wen; Tang, Liang; Qin, Chen-Jie; Lin, Yan; Zhang, Hui-Lu; Wu, Han; Ashton, Charles; Wu, Hong-Ping; Ding, Jin; Dong, Wei; Yu, Le-Xing; Yang, Wen; Huang, Dan-Dan; Wu, Meng-Chao; Wang, Hong-Yang; Yan, He-Xin
• Is Part Of: Oncoimmunology. Volume 5:Number 9(2016)
• Publication Date: 2016-09-01
• Subjects: Akt -- antitumor immunity -- dendritic cells -- SIRPα; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2016.1183850
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Despite their central function in tumor immunity, dendritic cells (DCs) can respond to inhibitory signals and become tolerogenic, curtailing T cell responses in vivo . Here, we provide the evidence for an inhibitory function of signal regulatory protein (SIRP) α in DC survival and activation. In tumors from human liver cancer patients, infiltrative DCs expressed elevated levels of SIRPα, which is correlated with the induction of immune tolerance within the tumors. Silencing of SIRPα resulted in a significant increase in the longevity of antigen-pulsed DCs in the draining lymph nodes. In addition, SIRPα controls the activation and output of DCs. Silencing of DC-expressed SIRPα induced spontaneous and enhanced production of IL12 and costimulatory molecules, resulting in more potent cytotoxic T lymphocyte responses, including the eradication of previously established solid tumors. SIRPα exerted such effects, at least in part, via the association and sequestration of p85 subunit of PI3K. Thus, SIRPα is a critical regulator of DC lifespan and activity, and its inhibition might improve the clinical efficacy of DC-based tumor vaccines.